In a recent meta-analysis of 71 RCTs29 and the large multinational CVD-REAL 2 study30, SGLT2 inhibitors significantly decreased MI and stroke events, as well as all-cause death and hospitalization for heart failure, suggesting their anti-atherothrombotic effects. The gene discussed is SLC5A2; the disease is stroke disorder.